POLE and neoplasm: In our study, we found that POLE amplified tumor samples exhibited 50% reduced mutation burden than tumors without POLE amplification in bladder urothelial carcinoma (BLCA) and OV (Figure 2C), suggesting that the gain-of-function POLE CNAmp may lead to an increased DDR function in cancer.